Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Houston, Texas

This page shows live ClinicalTrials.gov search results for Houston, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9744
Shown on this page
12
Local exact-city summaries
9744
Based on exact city/state matches in the local index.
Local exact-city recruiting
2038
Live official results below use the broader ClinicalTrials.gov location search.
The trial list below is retrieved from the live ClinicalTrials.gov search API for Houston, Texas. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Filter and sort this location

These controls apply only within Houston, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 1–12 of 9,744 matching trials in Houston, TX.
Indexed local directory records.
The summary panels and records below use exact city/state matches from the local directory for Houston, TX. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Indexed official records

Open in full search
Conditions
Castration-resistant Prostate Cancer (CRPC), ER+, HER 2- Breast Cancer, Microsatellite Stable (MSS) Colorectal Carcinoma, Non-small Cell Lung Cancer (NSCLC)
Interventions
Fulvestrant injection, IDE574
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
East Brunswick, New Jersey • Lake Success, New York • Austin, Texas + 6 more
Conditions
Diabetic Kidney Disease (DKD)
Interventions
ALN-ANG3, ALN-ANG3 placebo, Evinacumab, Evinacumab placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
51
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Huntington Beach, California + 42 more
Conditions
Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
Interventions
Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
152
States / cities
Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 124 more
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
COYA 302, Placebo
Drug
Lead sponsor
Coya Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more
Conditions
ICI-refractory, Non-Small Cell Lung Cancer
Interventions
SAR445877
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Recruiting Not applicable Interventional

Diagnosing Epilepsy To EffeCT Change

NCT07110337
Conditions
Epilepsy, Epilepsy (Treatment Refractory)
Interventions
Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
Device
Lead sponsor
Epiminder America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Phoenix, Arizona • Irvine, California • Palo Alto, California + 13 more
Conditions
Breast Cancer
Interventions
Moderately Hypofractionated Radiation, Ultrahypofractionated Radiation
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
4
States / cities
Loveland, Colorado • Voorhees Township, New Jersey • Houston, Texas + 1 more
Conditions
Endometrial Cancer, Malignant Solid Tumour
Interventions
Doxorubicin, Paclitaxel, Puxitatug Samrotecan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
66
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 57 more
Conditions
Chronic Low Back Pain (CLBP), Obesity, Overweight
Interventions
Placebo, Retatrutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more
Conditions
Metastatic Triple-Negative Breast Cancer
Interventions
Naxitamab, Sacituzumab govitecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
FGFR Gene Alterations, FGFR Gene Amplification, FGFR3 Gene Alteration, FGFR3 Gene Fusions, FGFR3 Gene Mutation, Low-grade NMIBC
Interventions
TYRA-300 50mg, TYRA-300 60mg, TYRA-300 Dose TBD
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 25 more
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
placebo, ponsegromab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
48
States / cities
Birmingham, Alabama • Bryant, Arkansas • Conway, Arkansas + 27 more